Brief: NRx Pharmaceuticals, Lotus Pharmaceuticals And Alvogen To Collaborate To Develop And Commercialize NRX-101

Lotus Pharmaceutical

05/06/2023 12:10

June 5 (Reuters) - Lotus Pharmaceutical Co Ltd
 1795.TW :
    * NRX PHARMACEUTICALS, LOTUS PHARMACEUTICALS AND ALVOGEN
INC.
ANNOUNCE COLLABORATION TO DEVELOP AND COMMERCIALIZE NRX-101
    * LOTUS PHARMACEUTICAL CO LTD -  RELATING TO NRX-101 FOR US
MARKET, NRX ENTITLED TO GET INITIAL PAYMENT OF $10 MILLION UPON
SOME SUCCESS-BASED MILESTONES
    * LOTUS PHARMACEUTICAL CO LTD - NRX TO RECEIVE AN ADDITIONAL
PAYMENT OF $5 MILLION UPON RECEIPT OF FDA APPROVAL FOR NRX-101
    * LOTUS PHARMACEUTICAL CO LTD - NRX ALSO ELIGIBLE TO RECEIVE
A
ROYALTY ON NET SALES BETWEEN 12% AND 16% CONTINGENT ON CERTAIN
SALES THRESHOLDS
    * LOTUS PHARMACEUTICAL CO LTD - NRX WOULD RECEIVE BONUS
MILESTONE
PAYMENTS OF UP TO $330 MILLION BASED ON REACHING CERTAIN NET
SALES TARGETS
    * LOTUS PHARMACEUTICAL CO LTD - LOTUS WILL ACQUIRE WORLDWIDE
RIGHTS FOR NRX-101 FOR TREATMENT OF S-TRBD
    * LOTUS PHARMACEUTICAL CO LTD -  LOTUS WILL BE RESPONSIBLE
FOR
COMMERCIALIZATION OF NRX-101 IN MARKETS OUTSIDE OF U.S.
    * LOTUS PHARMACEUTICAL CO LTD - NRX BELIEVE IT CAN FUND
OPERATIONS
UNTIL EXPECTED PHASE 2B/3 TRIAL DATA

Source text for Eikon:  ID:nGNX2Cr4Hj 
Further company coverage:  1795.TW